Oppenheimer analyst, Kevin DeGeeter, reiterated his Outperform on Novavax (NASDAQ: NVAX) but cut his price target to $1.25 (from $1.50) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE